Skye Bioscience Inc. is a biopharmaceutical company focused on developing next-generation molecules to treat obesity and metabolic diseases. The company aims to advance first-in-class drugs that can provide improved health outcomes for conditions with significant prevalence and unmet medical needs. Skye Bioscience is working on innovative therapeutic mechanisms, such as peripheral CB1 inhibition, to influence metabolic processes and improve weight management and related conditions. The firm is committed to pioneering drug candidates through design, manufacturing, and clinical development to address various diseases, particularly emphasizing the CB1 receptor. Based on their development pipeline, Skye Bioscience seeks to contribute meaningfully to the landscape of metabolic health, offering new possibilities for patients requiring diverse and effective treatment options.